OrganOx Limited is a UK-based medical device company specializing in organ preservation technologies for transplantation. A spin-out from the University of Oxford, it develops normothermic machine perfusion systems that keep donor livers functioning outside the body by circulating warm, oxygenated perfusate, enabling real-time assessment of organ viability and extending preservation times.
The company’s platform is used by transplant centers to increase utilization of available donor livers, including extended-criteria organs, by supporting functional evaluation prior to implantation. OrganOx supplies the perfusion device alongside single-use circuits, sensors, and related consumables, and provides clinical and technical support. Its solutions are deployed in Europe and other regions, with regulatory status varying by market. OrganOx is headquartered in Oxford, United Kingdom.
Effective June 1, 2026, he brings 20+ years at Terumo in sales, strategy and business development, including Chief of Staff experience, to scale commercial growth and NMP adoption.
Effective April 2026 the business segment will be renamed; the disclosure segment name will change starting with consolidated results for fiscal year ending March 2026.
